GlassScriptPhysician profile
Teresa Hsu
NPI 1114050929
$5,307.60
in general payments reported to CMS, 2019-2025
12 companies · $897 in 2025
The $897 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,189 · 2020: $198 · 2021: $134 · 2022: $464 · 2023: $582 · 2024: $843 · 2025: $897.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,322.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,322.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,625.66 | 2019-2025 | Myday Contact Lens, Misight Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $1,303.20 | 2019-2025 | Precision 1, Total30, Precision7 |
| Bausch & Lomb Americas INC. | $805.85 | 2022-2025 | Infuse, Miebo, Xiidra |
| Dompe US, INC. | $355.86 | 2022-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $314.88 | 2022-2024 | Cequa |
| Johnson & Johnson Vision Care, INC. | $295.61 | 2021-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $210.17 | 2019-2020 | |
| Tarsus Pharmaceuticals, INC. | $162.45 | 2025 | Xdemvy |
| Glaukos Corporation | $147.33 | 2023 | |
| Abb Con-Cise Optical Group LLC | $45.36 | 2025 | Spectacle Lenses, Contact Lens |
| Rxsight INC | $23.99 | 2025 | Light Adjustable Lens (Lal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teresa Hsu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.